Medical News

IMPRESS Study: Do Not Continue Gefitinib plus Chemotherapy beyond Radiologic Disease Progression in Advanced NSCLC

Primary results of Iressa Mutation-Positive Multicentre Treatment Beyond ProgRESsion Study (IMPRESS) had not shown difference between treatments...

11 Jan, 2018

Email this page
Nivolumab More Beneficial than Docetaxel in Advanced NSCLC Patients

Treatment with nivolumab, a programmed death -1 inhibitor, in previously treated patients with advanced non-small-cell lung cancer (NSCLC) delivered...

09 Jan, 2018

Email this page
Pembrolizumab Improves and Maintains Health-related QOL in Patients with Advanced NSCLC

A recent randomised, open-label, phase 3 trial reported the prespecified exploratory endpoint of pembrolizumab versus chemotherapy on patient-...

08 Jan, 2018

Email this page
No Improvement in Survival with Combined Bevacizumab and Adjuvant Chemotherapy in NSCLC

Bevacizumab has showed improved outcomes when added to platinum-based chemotherapy in advanced-stage non-squamous non-small-cell lung cancer (NSCLC...

05 Jan, 2018

Email this page


Lung Cancer: Changing Concepts that Pulmonologists Should Know


Dr. Douglas Arenberg
Associate Professor of Internal Medicine, University of Michigan Medical School Consulting Physician, Ann Arbor Veterans Administration Hospital, Michigan, USA
Hormonal Therapy in Management of Prostate Cancer: The Evolving Role


Panel Member: Dr Makarand Khochikar
MS, DNB (Urol), Dip. Urol (London), FICS, FRCS (Urol) (London)
Fellow of European Board of Urology, Head of Dept. of Uro-Oncology, Shri Siddhivinayak Ganapati Cancer Hospital, Miraj, Consultant Urologist, Ushahkal Nursing Home, Sangli, India
Panel Member: Dr Aditya Pradhan
MS (Gen. Surgery), DNB (Urol)
Senior Consultant Urologist, Dept. of Urology & Renal Transplantation, BLK Super Speciality Hospital, New Delhi, India
Panel Member: Dr K. Ramesh
Fellow of European Board of Urology Consultant Urologist & Robotic Surgeon Apollo Hospitals, Chennai, India
Moderator: Dr Anil Mandhani
Director-Uro-oncology & Minimally invasive Surgery Division of Urology & Renal Transplant Fortis Escorts, Delhi, India
Effective Doctor-Patient Communication - Module - 4: Role Plays & Conclusion


Dr. Anand Nadkarni
M.D., D.P.M., F.I.P.S.
Consultant Psychiatrist Institute for Psychological Health, Thane

Our Publications

Pomalong (Pomalidomide) Monograph

Pomalidomide-dexamethasone is a standard of care in patients with relapsed/refractory multiple myeloma following exhaustion of treatment options.

Q & A on Imatinib- Focused on CML

Imatinib, a tyrosine kinase inhibitor, induces durable responses in the majority of CML patients and is currently the standard of care for CML. This...

Q & A on Imatinib- Focused on GIST

Imatinib,a tyrosine kinase inhibitor, has been demonstrated to be effective in the treatment of unresectable or metastatic GISTs by inhibition of...

Erlotinib Update

This publication presents various studies on the anticancer drug, erlotinib.

Slide Library

Management of Advanced Prostate Cancer: Current Concepts

Prostate cancer has become a major public health burden worldwide and its incidence rates are increasing in India.  Hormonal therapy or androgen...

Email this page
Clinical Appraisal of Abiraterone acetate in Management of CRPC

Prostate cancer has become a major public health burden worldwide. Castration or hormonal therapy is the mainstay of treatment for the management of...

Email this page
HBV Reactivation in Patients Undergoing Chemotherapy

The risk of hepatitis B virus (HB) reactivation is high in patients receiving chemotherapy for solid or hematological malignancies which may lead to...

Email this page
Lung Cancer

This slide set provides information on types of lung cancer,epidemiology, pathophysiology, risk factors/causes, clinical features, diagnosis,...

Email this page

Key Trials

STRATUS Trial: POM+ LoDEX, Safe and Effective in Heavily Pretreated RRMM Patient

The STRATUS trial demonstrated safety and efficacy of pomalidomide plus low-dose dexamethasone in pretreated refractory /relapsed and refractory...

Pomalidomide plus Low-dose Dexamethasone More Effective in Patients with Relapsed and Refractory Multiple Myeloma Compared to High-dose Dexamethasone Alone

This trial compares efficacy and safety of pomalidomide plus low-dose dexamethasone and high-dose dexamethasone alone in relapsed and refractory...

Significant Reduction in the Risk of Treatment Failure with Bacillus Calmette-Guerin Therapy Compared to Chemotherapy in Carcinoma in Situ of the Bladder

A meta-analysis of randomized clinical trials concluded that intravesical Bacillus Calmette Guerin therapy was superior to chemotherapy in the...

Pomalidomide + Dexamethasone: Safe and Effective in RRMM Patients with Moderate Renal Impairment-II

Pomalidomide, low dose dexamethasone is safe and effective in moderate RI relapsed/refractory multiple myeloma patients. 

Patient Education

All You Wanted to Know about Prostate Cancer

Prostate is one of the most common cancers in men. This material describes risk factors, symptoms, diagnosis and treatment of prostate cancer. Also...

Living with Leukemia/Lymphoma

Tips for patient with leukaemia and lymphoma are explained along with pictures for better understanding. 

All You Wanted to Know about Ovarian Cancer

Risk factors, signs & symptoms, factors known to reduce ovarian cancer, diagnosis, treatment options and how to reduce risk of ovarian cancer...

Myths and Facts about Cancer

Throughout the years there have been many cancer myths floating around. This article will help clear the myths related to cancer.


Explore >>

Currently there is no content under this category.


Your choice of drug in the first-line treatment of patients with metastatic colorectal cancer treatment (CRC)
33% (1 vote)
Tegafur uracil
0% (0 votes)
67% (2 votes)
Total votes: 3